8-K filing — Rein Therapeutics, Inc. (RNTX)
Filed: 2026-09-04 AccNo: 0001193125-26-383726 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial
Global Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary FibrosisCompany on track to report initial topline data in 2H 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
Designation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:RNTX) with a Buy and maintains $8 price target.